Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
Liu R, Li Y, Tian L, Shi H, Wang J, Liang Y, Sun B, Wang S, Zhou M, Wu L, Nie J, Lin B, Tang S, Zhang Y, Wang G, Zhang C, Han J, Xu B, Liu L, Gong K, Zheng T.
Liu R, et al. Among authors: zhang c, zhang y.
Cancer Lett. 2019 Feb 28;443:34-46. doi: 10.1016/j.canlet.2018.11.030. Epub 2018 Nov 29.
Cancer Lett. 2019.
PMID: 30503555